Rivaroxaban Market Is Expected to Witness a CAGR of 1.5% over the Forecast Period (2018 – 2026)
Rivaroxaban, marketed as Xarelto, is a non-vitamin K antagonist oral anticoagulants (NOAC) that is used in the prevention or treatment of serious illnesses and potentially life-threatening conditions associated with blood coagulation. Rivaroxaban was discovered by Bayer and is being jointly developed with Janssen Research & Development, LLC.
View full press release